Industry Explorers Blaze On
-
An Outsourcing Future Of Information Sharing And Commercial Streamlining
12/1/2023
Outsourced Pharma Chief Editor Louis Garguilo writes about what outsourcing professionals think about the future of working with CDMOs.
-
Executive Outlook: Converting Innovative Science Into Predictable Returns
12/1/2023
Executives at Big Pharma and small biotech will be rewarded in 2024 if they can find new ways to develop and commercialize drugs in the context of an unforgiving investment, payer, and regulatory landscape.
-
Defining A Competitive Next-Gen RNA Therapeutic In 2024
12/1/2023
To start singling-out where the opportunities exist to craft the next generation of RNA therapeutics, Anna Rose Welch sat down with four RNA executives.
-
Biopharma’s Eminent Challenges In 2024 — Inside & Out
12/1/2023
A baker’s dozen of biopharma CEOs answer a call to prioritize and describe challenges they expect to face in the coming year.
-
Top 2024 Clinical Trial Site Challenges: Staffing & Technology
12/1/2023
Industry experts talk about some of the new challenges facing clinical trial sites in 2024.
-
Finance And Funding: Anticipating Improvement, Planning For Uncertainty
12/1/2023
Executives responding to this year’s finance and funding outlook questions are optimistic about the potential for a turnaround in 2024.
-
Moving Beyond AAV: The Next Generation Of Vectors In CGT
12/1/2023
We catch up with Dr. Konstantin Konstantinov, CTO at Ring Therapeutics, and Ryan Crisman, Ph.D., cofounder and CTO at Umoja Biopharma, to get their thoughts on the future of new anellovirus vectors and existing lentiviral vector technology for in vivo gene delivery respectively.
-
You Can Increase Your Odds Of Hiring And Retaining The Best Talent
12/1/2023
Finding scientific talent is an arduous process, often stealing precious time from our calendars. Furthermore, hiring well doesn’t have to be left to chance. Try these specific actions.
-
Top 10 Reasons For Oral Dose CMO Preference
12/1/2023
Just under one-third of respondents who participated in ISR’s Oral Dosage Forms Market Outlook research shared that Familiarity/History of working together/Prior positive experience are the reasons behind their preferences.
-
Accelerating Drug Development With Real World Data
12/1/2023
Think real-world data’s only application is clinical trials? Think again. Savvy early-stage biotechs are leveraging RWD in their formative stages, long before entering the clinic, to drive critical efficiencies in drug discovery and development.